期刊文献+

鬼臼毒素衍生物CIP-36诱导KBV200细胞凋亡 被引量:7

CIP-36,a novel podophyllotoxin derivative,induces the apoptosis of KBV200 cells
下载PDF
导出
摘要 目的研究鬼臼毒素衍生物CIP-36对多药耐药人口腔鳞状上皮癌细胞KBV200的抗肿瘤活性及其作用机制。方法MTT法考察CIP-36对KBV200体外增殖的抑制作用;Giemsa染色、DNAladder和流式细胞仪等方法进行细胞凋亡检测;免疫荧光法观察CIP-36对细胞骨架的作用;West-ernblot法检测CIP-36对KBV200细胞P-glycoprotein表达的影响。结果CIP-36对KBV200细胞有明显的抑制作用,IC50值为(2.06±0.38)μmol.L-1,能够诱导细胞产生凋亡小体和DNAladder。流式细胞检测到了细胞凋亡峰,并观察到细胞周期出现S/G2+M期阻滞。Westernblot结果显示P-gp表达降低,并且观察到CIP-36可破坏KBV200细胞的细胞骨架。结论CIP-36可能通过降低P-gp的表达,破坏细胞骨架等多靶点克服KBV200细胞株的多药耐药性。 Aim To study the antitumor activity of CIP-36 on multidrug resistance human oral squamous carcinoma cell(KBV200 cells)in vitro and the feasible anticancer mechanisms.Methods MTT assay,morphological study,DNA gel electrophoresis,flow cytometry,Western blot,and immunofluorescence were carried out.Results:The IC50 value of CIP-36 on KBV200 cells was(2.06±0.38)μmol·L^-1.After KBV200 cells were treated by CIP-36,the apparent morphological characteristic and typical DNA ladder were all detected.Both the number of apoptosis cells and the cell cycle were measured by flow cytometric.A typical "Sub-G1 peak" was checked and CIP-36 blocked the cell cycle at S/G2+M phase.Western-blot showed that the expression of P-glycoprotein was decreased.CIP-36 could interfere with microtubule polymerization and disrupt cytoskeleton.Conclusions CIP-36 has the potentiality to overcome P-glycoprotein-mediated multidrug resistance in the KBV200 cell line.
出处 《中国药理学通报》 CAS CSCD 北大核心 2010年第5期607-610,共4页 Chinese Pharmacological Bulletin
基金 国家自然科学基金资助项目(No30873363) 天津市自然科学基金重点资助项目(No08JCYBJC070000) 天津市自然科学重点支持项目(No09ZCKFNC01200)
关键词 CIP-36 鬼臼毒素衍生物 细胞周期 多药耐药 P糖蛋白 微管 CIP-36 Podophyllotoxin derivative cell cycle P-glycoprotein microtubule
  • 相关文献

参考文献9

  • 1Issell B F.The podophyllotoxin derivatives VP16-213 and VM26[J].Cancer Chemother Pharmacol,1982,7(2-3):73-80.
  • 2Lum B L,Kaubisch S,Yahanda A M,et al.Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance[J].J Clin Oncol,1992,10(10):1635-42.
  • 3纪舒昱,翁稚颖,周轶平,冯耀宇,李玛琳.8种有机溶剂对肿瘤细胞的细胞毒作用[J].云南大学学报(自然科学版),2001,23(6):457-460. 被引量:21
  • 4Bacher G,Nickel B,Emig P,et al.D-24851,a novel synthetic microtubule inhibitor,exerts curative antitumoral activity in vivo,shows eficacy toward muhidrug-resistant tumor cells,and lacks neurotoxicity[J].Cancer Res,2001,61(1):392-9.
  • 5王辉,雷志勇,陈虹,冷玲,柯颖,曹波.土槿乙酸衍生物PB-LY体外抗肿瘤作用及其机制研究[J].中国药理学通报,2008,24(9):1204-1208. 被引量:6
  • 6于韬,赵桂森,臧恒昌,牛华英,景永奎.肿瘤多药耐药逆转剂研究进展[J].中国药物化学杂志,2003,13(3):172-178. 被引量:16
  • 7Marzolini C,Paus E,Buclin T,et al.Polymophisma in human MDR1(P-glycoprotein):recent advances and clinical relevance[J].Clin Pharmacol Ther,2004,75(1):13-33.
  • 8Kiselyov A,Balakin K V,Tkachenko S E,et al.Recent progress in discovery and development of antimitotic agents[J].Anticancer Agents Med Chem,2007,7(2):189-208.
  • 9Fumoleau P,Coudert B,Isambert N.Novel tubulin-targeting agents:anticancer activity and pharmacologic profile of epothilones and related analogues[J].Ann Oncol,2007,18(5):9 -15.

二级参考文献42

  • 1刘晓翌,刘建军.Caspase与细胞凋亡[J].武汉大学学报(医学版),2004,25(6):742-745. 被引量:19
  • 2周建军,乐秀芳,韩家娴,杨蔚怡.评价抗癌物质活性的改良MTT方法[J].中国医药工业杂志,1993,24(10):455-457. 被引量:107
  • 3杨远和,Bern.,IA.二甲亚砜对人表皮的核酸和蛋白质合成的影响[J].中华劳动卫生职业病杂志,1994,12(1):32-34. 被引量:6
  • 4熊斌,雷志勇,陈虹,刘斌,白淑芳.土槿乙酸衍生物PBA-D1诱导Hela细胞凋亡及其机制[J].中国药理学通报,2005,21(7):867-871. 被引量:14
  • 5Scagliotti GV, Novello S, Selvaggi G. Multidrug resistance in non-small-eell lung cancer I J]. Ann Oneol,1999,10(5 suppl. ) :81 - 84.
  • 6Stein U, Walther W. Cytokine-mediated reveral of multidrug resistance [ J ]. Cytotech, 1998, 27 ( 1/3 ) :271 - 282.
  • 7Teodori E, Dei S, Quidu P, et al. Design, synthesis,and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range [ J ]. J Med Chem, 1999, 42 ( 10 ) :1687- 1697.
  • 8Gilles K, Leming MS, Avner R. Quantitative strueture-aetivity relationship of multidrug resistanee reversal agents [J]. Mol Pharrnacol, 1997, 52(2) : 323- 334.
  • 9Naito M, Tsuruo T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833 [ J ]. Cancer Chemother Pharmacol, 1997, 40(suppl. ) :20 - 24.
  • 10Solary E, Mannone L, Moreau D, et al. Phase I study of einehonine, a multidrug resistance reversing agent,combined with the CHVP regimen in relapsed and refractory lymphoprtliferative syndromes [ J ]. Leukemia,2000, 14(12) :2085 - 2094.

共引文献38

同被引文献82

引证文献7

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部